Ibio Inc (IBIO)
NASDAQ:IBIO
Want to see IBIO full AI Analyst Report?
Top Page
Ibio
(NASDAQ:IBIO)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.00
▼(-2.91% Downside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by very weak financial performance (minimal revenue, sizeable losses, and persistent cash burn) and a bearish technical setup (below major moving averages with negative MACD). Pipeline and governance-related corporate updates provide some support, but they do not outweigh the current fundamentals and price-trend weakness.
Positive Factors
Clinical-stage transition (IBIO-600 Phase 1)
Advancing IBIO-600 into a first-in-human Phase 1 trial materially de-risks preclinical program risk and creates durable value inflection points (safety/PK data, cohort readouts) that can catalyze partnerships, milestone payments, and more definitive strategic choices over the next 2–6 months.
Negative Factors
Persistent cash burn and negative operating cash flow
Sustained negative operating and free cash flow means the business cannot self-fund development; this structural cash burn necessitates ongoing external financing, increasing dilution risk and constraining the company’s ability to advance multiple programs or scale operations without securing new capital or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical-stage transition (IBIO-600 Phase 1)
Advancing IBIO-600 into a first-in-human Phase 1 trial materially de-risks preclinical program risk and creates durable value inflection points (safety/PK data, cohort readouts) that can catalyze partnerships, milestone payments, and more definitive strategic choices over the next 2–6 months.
Read all positive factors
Ibio (IBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$91.41M
Dividend YieldN/A
Average Volume (3M)941.86K
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue Growth-20.00%
EPS Growth75.26%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.58
Shares Outstanding49,678,562
10 Day Avg. Volume717,551
30 Day Avg. Volume941,862
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.54
Price to Sales (P/S)20.03
P/FCF Ratio-0.52
Enterprise Value/Market Cap-0.18
Enterprise Value/Revenue-54.18
Enterprise Value/Gross Profit33.86
Enterprise Value/Ebitda0.72
Forecast
1Y Price Target
$5.80Price Target Upside181.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$180.00K
Ibio Business Overview & Revenue Model
Company Description
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead the...
How the Company Makes Money
iBio’s revenue model is primarily tied to biopharmaceutical R&D and monetization of its technology and product candidates. Potential and historical sources of cash generation can include: (1) out-licensing or partnering its drug candidates or unde...
Ibio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 300.00K | 400.00K | 225.00K | 0.00 | 1.88M | 2.37M |
| Gross Profit | -480.00K | 400.00K | 225.00K | 0.00 | -1.91M | 909.00K |
| EBITDA | -22.55M | -17.04M | -14.02M | -27.85M | -25.72M | -28.55M |
| Net Income | -27.61M | -18.38M | -24.91M | -65.01M | -50.39M | -23.21M |
Balance Sheet | ||||||
| Total Assets | 85.83M | 23.18M | 28.73M | 41.21M | 99.41M | 146.97M |
| Cash, Cash Equivalents and Short-Term Investments | 74.80M | 8.58M | 14.21M | 7.33M | 33.52M | 96.97M |
| Total Debt | 2.33M | 3.51M | 4.46M | 17.07M | 25.77M | 32.72M |
| Total Liabilities | 8.30M | 8.30M | 7.41M | 25.83M | 35.92M | 38.40M |
| Stockholders Equity | 77.54M | 14.88M | 21.32M | 15.38M | 63.48M | 108.58M |
Cash Flow | ||||||
| Free Cash Flow | -22.16M | -15.32M | -18.76M | -36.17M | -45.13M | -35.23M |
| Operating Cash Flow | -21.61M | -15.30M | -18.55M | -30.44M | -37.80M | -30.06M |
| Investing Cash Flow | -27.54M | 742.00K | 906.00K | 7.01M | -5.13M | -26.48M |
| Financing Cash Flow | 91.82M | 8.93M | 24.49M | 2.30M | -5.80M | 78.83M |
Ibio Technical Analysis
Positive
2.06
Price Trends
1.89
Negative
2.13
Negative
1.63
Positive
Market Momentum
-0.06
Negative
54.69
Neutral
83.38
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Positive. The current price of 2.06 is above the 20-day moving average (MA) of 1.64, above the 50-day MA of 1.89, and above the 200-day MA of 1.63, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 54.69 is Neutral, neither overbought nor oversold. The STOCH value of 83.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBIO.
Ibio Risk Analysis
Ibio disclosed 59 risk factors in its most recent earnings report. Ibio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ibio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $14.54M | -1.77 | -89.92% | ― | ― | 63.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $245.06M | -0.53 | 359.80% | ― | ― | -3629.03% | |
43 Neutral | $4.89M | -1.01 | -79.47% | ― | -100.00% | 62.88% | |
42 Neutral | $91.41M | ― | -53.86% | ― | -20.00% | 75.26% | |
42 Neutral | $5.47M | -0.15 | -1292.87% | ― | ― | -72.78% |
* Healthcare Sector Average
IBIO
Ibio
1.84
1.02
124.94%
NERV
Minerva Neurosciences
5.26
3.80
260.27%
PULM
Pulmatrix
1.34
-5.47
-80.32%
CMMB
Chemomab Therapeutics
2.02
-3.58
-63.93%
ASBP
Aspire Biopharma Holdings
5.41
-264.59
-98.00%
FBLG
FibroBiologics, Inc.
1.05
-15.15
-93.52%
Ibio Corporate Events
Business Operations and StrategyExecutive/Board Changes
iBio Strengthens Board with Appointment of Dr. Stoner
Positive
May 8, 2026
On May 7, 2026, iBio’s board appointed veteran biotech executive Dr. Elizabeth Stoner as a Class II director and member of the Compensation Committee, filling the vacancy created by the same-day resignation of director Evert Schimmelpennink,...
Business Operations and StrategyProduct-Related Announcements
iBio Advances to Clinical Stage With IBIO-600 Trial
Positive
Apr 8, 2026
On April 8, 2026, iBio announced it had received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, clearing the way for a first-in-human ...
Business Operations and StrategyProduct-Related Announcements
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential
Positive
Mar 9, 2026
On March 9, 2026, iBio reported preclinical body composition data from an obese non-human primate study of IBIO-610, a potential first-in-class Activin E antibody for fat-selective weight loss and related cardiometabolic conditions. In this small,...
Business Operations and StrategyPrivate Placements and Financing
Ibio Ends At-The-Market Equity Offering Program
Negative
Feb 27, 2026
On February 23, 2026, Ibio terminated its At Market Issuance Sales Agreement with Chardan Capital Markets LLC and Craig-Hallum Capital Group LLC, which had been in place since July 3, 2024. As a result, the company also ended its at-the-market pro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.